The incidence of engraftment on day D+30 was achieved at 89.3%; The cumulative incidence of relapse at 2 year was 17, 8%; The incidence of infection was 71, 4%, CMV reactivation was 92, 8%; The cumulative incidence of acute graft-versus-host disease (GVHD) grades I to II and grades III to IV was 14, 3% and 14, 3%, and of chronic GVHD was 17, 8% and 7, 1%.